Experienced in Strongyloidiasis

Dr. Armando E. Acevedo

Pediatrics | General Practice
Acevedo Medical Care Group Inc
2400 Nw 54th St, 
Miami, FL 
Accepting New Patients
Offers Telehealth
Experienced in Strongyloidiasis
Acevedo Medical Care Group Inc
2400 Nw 54th St, 
Miami, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Armando Acevedo is a primary care provider, a Pediatrics specialist and a General Practice provider in Miami, Florida. Dr. Acevedo is rated as an Experienced provider by MediFind in the treatment of Strongyloidiasis. His top areas of expertise are Asthma, Obesity, Asthma in Children, and Obesity in Children. Dr. Acevedo is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatrics
General Practice
Licenses
Specialist in FL
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
View 7 Less Insurance Carriers -

Locations

ACEVEDO MEDICAL CARE GROUP INC
2400 Nw 54th St, Miami, FL 33142

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomised, Double-blind, Parallel Group, Multicentre, Stratified, Study Evaluating the Efficacy and Safety of Once Daily Fluticasone Furoate/Vilanterol Inhalation Powder Compared to Once Daily Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Participants Aged 5 to 17 Years Old (Inclusive) Currently Uncontrolled on Inhaled Corticosteroids
A Randomised, Double-blind, Parallel Group, Multicentre, Stratified, Study Evaluating the Efficacy and Safety of Once Daily Fluticasone Furoate/Vilanterol Inhalation Powder Compared to Once Daily Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Participants Aged 5 to 17 Years Old (Inclusive) Currently Uncontrolled on Inhaled Corticosteroids
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drugs: Fluticasone Furoate, Vilanterol
Study Phase: Phase 3
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Biological
Study Phase: Phase 3
Study HZA114971, A Multicentre Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of a One-Year Regimen of Orally Inhaled Fluticasone Furoate 50 mcg Once Daily on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma
Study HZA114971, A Multicentre Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of a One-Year Regimen of Orally Inhaled Fluticasone Furoate 50 mcg Once Daily on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma
Enrollment Status: Completed
Publish Date: January 17, 2024
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Terminated
Publish Date: June 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: June 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

1 Total Publications

A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants.
A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants.
Journal: The Journal of infectious diseases
Published: July 11, 2024
Similar Doctors
Advanced in Strongyloidiasis
Dr. Araceli Yapor
General Practice
Advanced in Strongyloidiasis
Dr. Araceli Yapor
General Practice
7975 Nw 154th St, Suite 270, 
Miami Lakes, FL 
 (8.5 miles away)
305-698-6030
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Araceli Yapor is a primary care provider, practicing in General Practice in Miami Lakes, Florida. Dr. Yapor is rated as an Advanced provider by MediFind in the treatment of Strongyloidiasis. Her top areas of expertise are Obesity, Oral Herpes, Sitosterolemia, and Vitamin D Deficiency. Dr. Yapor is currently accepting new patients.

Experienced in Strongyloidiasis
Dr. Jose J. Villar
General Practice
Experienced in Strongyloidiasis
Dr. Jose J. Villar
General Practice

Claremedica Viking LLC

12996 W Dixie Hwy, 
North Miami, FL 
 (5.9 miles away)
305-592-5214
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Jose Villar is a primary care provider, practicing in General Practice in North Miami, Florida. Dr. Villar is rated as an Advanced provider by MediFind in the treatment of Strongyloidiasis. His top areas of expertise are Type 2 Diabetes (T2D), Cirrhosis, Heart Failure with Preserved Ejection Fraction (HFpEF), and Hypertensive Heart Disease. Dr. Villar is currently accepting new patients.

Experienced in Strongyloidiasis
Dr. Rafael O. Nunez
Pediatrics | Internal Medicine
Experienced in Strongyloidiasis
Dr. Rafael O. Nunez
Pediatrics | Internal Medicine

Soma Medical Center PA 10

1402 Royal Palm Beach Blvd, Suite 200, 
Royal Palm Beach, FL 
 (61.2 miles away)
561-907-4888
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Rafael Nunez is a primary care provider, practicing in Pediatrics and Internal Medicine in Royal Palm Beach, Florida. Dr. Nunez is rated as a Distinguished provider by MediFind in the treatment of Strongyloidiasis. His top areas of expertise are High Cholesterol, Cirrhosis, Xanthoma, and Familial Combined Hyperlipidemia. Dr. Nunez is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Acevedo's expertise for a condition
ConditionClose
        View All 52 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile